InvestorsHub Logo
Followers 87
Posts 6692
Boards Moderated 1
Alias Born 09/18/2009

Re: Skiluc post# 35966

Friday, 04/01/2022 7:16:17 PM

Friday, April 01, 2022 7:16:17 PM

Post# of 42921
It's an interesting transition, going from getting the company to do what you want it to do for you, to then doing what the company requires of you to do for it. I think we're about to see lenz expand the company's direction further than what may have been planned, especially in terms of our governmental partnerships. And yes, I think that's going to help lead to a positive future.

I'm in my 20th quarter now as a shareholder, and I get a little too impatient at times. I've got no appreciation of "puff pieces" from Wainwright and Oppenheimer, as we get. When the company announces news in regards to Lancet, at this time, when we're all expecting a peer-review of our updated results, it's extremely frustrating to find that the Lancet news was that Humanigen is featured on the cover. Was that the editor's choice, or did we pay for that? I think many of us were hoping the Lancet news was going to be more than it turned out to be.

But I have never wavered in my faith in this drug, or in Dale and Cameron. It is virtually impossible for a micro-cap biotech to do what Humanigen is on the verge of doing. But this drug, and this management team, are going to bring a blockbuster novel therapeutic to market. It will save the lives of hundreds of thousands of patients as it gets commercialized, and it will change the lives of tens of thousands of shareholders.